Author/Authors :
Gaddipati, Vamsi C. Department of Cardiovascular Sciences - Morsani College of Medicine - University of South Florida, Tampa, USA , Patel, Aarti A. Department of Cardiovascular Sciences - Morsani College of Medicine - University of South Florida, Tampa, USA , Cohen, Adam J. Department of Cardiovascular Sciences - Morsani College of Medicine - University of South Florida, Tampa, USA
Abstract :
Peripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with
development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the
use of typical drug therapy for the treatment of heart failure. Pregnancy-associated cardiomyopathy (PACM) is a similar condition
that refers to patients who develop such symptoms prior to the last month of pregnancy. We report the case of a nulliparous
Caucasian female who develops early, severe PACM during her first pregnancy with postpartum persistence of New York Heart
Association class II-III symptoms despite medical therapy. The use of the novel heart failure agent, sacubitril/valsartan (Entresto),
is initiated with near-complete resolution of her symptoms.
